We identify decreased TGF-β signaling in breast, kidney, and gastric cancers; increased TGF-β signaling in lung and bladder cancers; and no significant change in the other aforementioned cohorts (Figure S4A). This evidence concerns the gene TGFB1 and urinary bladder cancer.